Equities Analysts Issue Forecasts for RAPP FY2026 Earnings

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – HC Wainwright upped their FY2026 earnings estimates for Rapport Therapeutics in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($3.18) per share for the year, up from their prior estimate of ($4.51). HC Wainwright currently has a “Buy” rating and a $66.00 target price on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.34) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q4 2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.91) EPS, Q2 2027 earnings at ($1.06) EPS, Q3 2027 earnings at ($1.12) EPS, Q4 2027 earnings at ($1.19) EPS, FY2027 earnings at ($4.29) EPS, FY2028 earnings at ($5.37) EPS, FY2029 earnings at ($5.56) EPS and FY2030 earnings at ($4.58) EPS.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.36.

RAPP has been the topic of several other reports. Wall Street Zen raised Rapport Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. William Blair assumed coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating for the company. Wolfe Research began coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They set an “outperform” rating and a $50.00 price objective for the company. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Tuesday, October 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $64.50.

Rapport Therapeutics Stock Up 6.7%

Shares of NASDAQ RAPP opened at $26.07 on Monday. The business has a fifty day moving average price of $33.70 and a two-hundred day moving average price of $35.52. Rapport Therapeutics has a fifty-two week low of $22.06 and a fifty-two week high of $52.93.

Insiders Place Their Bets

In related news, Director Wendy B. Young bought 3,789 shares of the company’s stock in a transaction dated Thursday, October 22nd. The stock was purchased at an average price of $26.39 per share, with a total value of $99,991.71. Following the completion of the acquisition, the director owned 13,289 shares of the company’s stock, valued at $350,696.71. The trade was a 39.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Maraganore purchased 9,411 shares of Rapport Therapeutics stock in a transaction dated Thursday, October 22nd. The stock was bought at an average price of $26.45 per share, for a total transaction of $248,920.95. Following the completion of the purchase, the director owned 9,411 shares in the company, valued at $248,920.95. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 1,031,174 shares of company stock valued at $22,023,898 and sold 46,477 shares valued at $1,958,709. 12.48% of the stock is owned by corporate insiders.

Institutional Trading of Rapport Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RAPP. Algert Global LLC bought a new position in Rapport Therapeutics in the second quarter valued at about $9,327,000. Johnson & Johnson bought a new stake in shares of Rapport Therapeutics during the second quarter worth about $74,360,823. Legal & General Group Plc acquired a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $940,000. Bank of America Corp DE acquired a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $3,170,000. Finally, Walleye Capital LLC bought a new position in Rapport Therapeutics in the 2nd quarter valued at approximately $4,257,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics is a Boston-based biotechnology company developing medicines for neurological and psychiatric disorders. Founded in 2022, the company focuses on small molecules designed to act on mechanisms that regulate the movement and function of proteins in the brain.

Its research platform is intended to identify targets involved in neuronal signaling, including interactions that influence ion channels. Rapport’s pipeline includes RAP-219, an investigational medicine that modulates AMPA receptors and is being developed for focal epilepsy.

The company’s work is centered on discovering and developing treatments for conditions with limited or inadequate therapeutic options.